Nanotechnology-mediated Targeting of Tumor Angiogenesis

Overview

Journal Vasc Cell

Date 2011 Feb 26

PMID 21349160

Citations 31

Authors

Deboshri Banerjee

Rania Harfouche

Shiladitya Sengupta

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is disregulated in many diseased states, most notably in cancer. An emerging strategy for the development of therapies targeting tumor-associated angiogenesis is to harness the potential of nanotechnology to improve the pharmacology of chemotherapeutics, including anti-angiogenic agents. Nanoparticles confer several advantages over that of free drugs, including their capability to carry high payloads of therapeutic agents, confer increased half-life and reduced toxicity to the drugs, and provide means for selective targeting of the tumor tissue and vasculature. The plethora of nanovectors available, in addition to the various methods available to combine them with anti-angiogenic drugs, allows researchers to fine-tune the pharmacological profile of the drugs ad infinitum. Use of nanovectors has also opened up novel avenues for non-invasive imaging of tumor angiogenesis. Herein, we review the types of nanovector and therapeutic/diagnostic agent combinations used in targeting tumor angiogenesis.

Citing Articles

The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?.

Takac P, Michalkova R, cizmarikova M, Bedlovicova Z, Balazova L, Takacova G Life (Basel). 2023; 13(2).

PMID: 36836823 PMC: 9965924. DOI: 10.3390/life13020466.

An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis.

Yan H, Zhang J, Leung K, Lo K, Yu J, To K Cancers (Basel). 2023; 15(3).

PMID: 36765694 PMC: 9913146. DOI: 10.3390/cancers15030736.

Effective treatment of intractable diseases using nanoparticles to interfere with vascular supply and angiogenic process.

Hoseinzadeh A, Ghoddusi Johari H, Anbardar M, Tayebi L, Vafa E, Abbasi M Eur J Med Res. 2022; 27(1):232.

PMID: 36333816 PMC: 9636835. DOI: 10.1186/s40001-022-00833-6.

Smart and Multi-Functional Magnetic Nanoparticles for Cancer Treatment Applications: Clinical Challenges and Future Prospects.

Aram E, Moeni M, Abedizadeh R, Sabour D, Sadeghi-Abandansari H, Gardy J Nanomaterials (Basel). 2022; 12(20).

PMID: 36296756 PMC: 9611246. DOI: 10.3390/nano12203567.

Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Chakraborty K, Tripathi A, Mishra S, Mallick A, Sinha Roy R Biosci Rep. 2022; 42(7).

PMID: 35638450 PMC: 9272595. DOI: 10.1042/BSR20212051.

References

Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T . Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm. 2007; 342(1-2):194-200. DOI: 10.1016/j.ijpharm.2007.04.037. View

Banerjee D, Liu A, Voss N, Schmid S, Finn M . Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. Chembiochem. 2010; 11(9):1273-9. PMC: 4180096. DOI: 10.1002/cbic.201000125. View

Gurunathan S, Lee K, Kalishwaralal K, Sheikpranbabu S, Vaidyanathan R, Eom S . Antiangiogenic properties of silver nanoparticles. Biomaterials. 2009; 30(31):6341-50. DOI: 10.1016/j.biomaterials.2009.08.008. View

Couvreur P, Vauthier C . Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006; 23(7):1417-50. DOI: 10.1007/s11095-006-0284-8. View

Willis M, Collins B, Zhang T, Green L, Sebesta D, Bell C . Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem. 1998; 9(5):573-82. DOI: 10.1021/bc980002x. View

Xu Y, Wen Z, Xu Z . Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Anticancer Res. 2010; 29(12):5103-9. View

Khodarev N, Yu J, Labay E, Darga T, Brown C, Mauceri H . Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci. 2003; 116(Pt 6):1013-22. DOI: 10.1242/jcs.00281. View

Li L, Wartchow C, Danthi S, Shen Z, DeChene N, Pease J . A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004; 58(4):1215-27. DOI: 10.1016/j.ijrobp.2003.10.057. View

Xie J, Shen Z, Li K, Danthi N . Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle. Int J Nanomedicine. 2007; 2(3):479-85. PMC: 2676654. View

10.

Anderson S, Rader R, Westlin W, Null C, Jackson D, Lanza G . Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 2000; 44(3):433-9. DOI: 10.1002/1522-2594(200009)44:3<433::aid-mrm14>3.0.co;2-9. View

11.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

12.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

13.

Hebbar M, Peyrat J . Significance of soluble endothelial molecule E-selectin in patients with breast cancer. Int J Biol Markers. 2000; 15(1):15-21. DOI: 10.1177/172460080001500103. View

14.

Ferrara N . VEGF as a therapeutic target in cancer. Oncology. 2005; 69 Suppl 3:11-6. DOI: 10.1159/000088479. View

15.

Zhao B, Hoffmann F . Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell. 2006; 17(9):3819-31. PMC: 1556379. DOI: 10.1091/mbc.e05-10-0990. View

16.

Satchi-Fainaro R, Mamluk R, Wang L, Short S, Nagy J, Feng D . Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 2005; 7(3):251-61. DOI: 10.1016/j.ccr.2005.02.007. View

17.

Mulder W, van der Schaft D, Hautvast P, Strijkers G, Koning G, Storm G . Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007; 21(2):378-83. DOI: 10.1096/fj.06-6791com. View

18.

Samei E, Saunders R, Badea C, Ghaghada K, Hedlund L, Qi Y . Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent. Int J Nanomedicine. 2009; 4:277-82. PMC: 2789439. View

19.

Winet H, Hollinger J, Stevanovic M . Incorporation of polylactide-polyglycolide in a cortical defect: neoangiogenesis and blood supply in a bone chamber. J Orthop Res. 1995; 13(5):679-89. DOI: 10.1002/jor.1100130507. View

20.

Chen J, Wu H, Han D, Xie C . Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 2006; 231(2):169-75. DOI: 10.1016/j.canlet.2005.01.024. View